Hankins joins MUSC Foundation for Research Development

Mark Hankins

Mark Hankins has joined MUSC Foundation for Research Development (FRD) as its director of licensing.  In this role, he will assist MUSC faculty in commercializing their inventions and protecting their intellectual property (IP).  Hankins will also market MUSC technologies to prospective licensees, and negotiate licenses or other IP agreements to facilitate the commercialization of MUSC inventions.

“The MUSC community is looking forward to Mark’s contribution,” said Michael Rusnak, FRD executive director. “His broad experience in both industry and academia with definitely be an asset to our organization and we are thrilled to have him on board.”

Hankins has more than 25 years of experience in the health care industry, including positions with startup companies, large pharmaceutical companies, emerging pharmaceutical companies, and government organizations.  Most recently, Hankins has been serving as an executive consultant to early stage and start-up companies focused primarily on therapeutic products and medical devices.  Prior to his consulting work, he was CEO of Codevax, a vaccine start-up in Rochester, NY and held vice president of business development positions for CIMA Labs and Cardinal Health.  Hankins has held senior business development and licensing positions with Sanofi Pasteur in both the U.S. and Canada.  Hankins began his health care career as a technology licensing specialist at the National Institutes of Health.

Hankins is a patent attorney, member of the Georgia State Bar, and a Certified Licensing Professional.  He holds a Juris Doctor from University of Georgia School of Law, a Master of Science in Biotechnology from Johns Hopkins University, and a Bachelor of Arts in Political Science and Economics from Emory University.

About MUSC Foundation for Research Development
FRD has served as MUSC’s technology transfer office since 1998. During that period, FRD has filed patent applications on more than 400 technologies, resulting in over 150 U.S. issued patents. Additionally, FRD has executed more than 150 licenses and spun out more than 50 startup companies. MUSC startups have had products approved by the FDA and acquired by publicly traded corporations while attracting substantial investment dollars into South Carolina. Innovations from MUSC, including medical devices, therapies and software, are positively impacting health care worldwide. Please visit frd.musc.edu